Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer

This study tests the safety and effectiveness of a new drug called BEY1107 — either on its own or combined with a standard chemotherapy drug called gemcitabine — in patients with pancreatic cancer. **You may be eligible if...** - You have been diagnosed with pancreatic ductal adenocarcinoma or undifferentiated pancreatic carcinoma, confirmed by biopsy or cytology - You have at least one tumor that can be measured on a scan - Your ability to carry out daily activities is rated 0, 1, or 2 on the standard medical scale - You have a life expectancy of at least 12 weeks - Your bone marrow, kidney, and liver function meet the required levels **You may NOT be eligible if...** - You have previously received treatment for locally advanced or metastatic pancreatic cancer - You recently had major surgery - You have uncontrolled cancer that has spread to the brain - You have an active serious bacterial infection Talk to your doctor to see if this trial is right for you.